Effect of chromium supplementation and exercise on body composition, resting metabolic rate and selected biochemical parameters in moderately obese women following an exercise program.
OBJECTIVE
To investigate the effect of chromium picolinate (CP) supplementation on body composition, resting metabolic rate (RMR), selected biochemical parameters and iron and zinc status in moderately obese women participating in a 12-week exercise program.


METHODS
Forty-four women, 27 to 51 years of age, were randomly assigned to two groups based on their body mass index. Subjects received either 400 microg/day of chromium as a CP supplement or a placebo in double-blind fashion and participated in a supervised weight-training and walking program two days per week for 12 weeks. Body composition and RMR were measured at baseline, 6 and 12 weeks. Selected biochemical parameters and iron and zinc status were measured at baseline and 12 weeks.


RESULTS
Body composition and RMR were not significantly changed by CP supplementation. No significant differences in fasting plasma glucose, serum insulin, plasma glucagon, serum C-peptide and serum lipid concentrations or in iron and zinc indices were found between the two groups over time. Serum total cholesterol concentration significantly decreased (p = 0.0016) over time for all subjects combined, probably as a result of the exercise training. Exercise training significantly reduced total iron binding capacity (TIBC) by 3% for all subjects combined (p = 0.001 1).


CONCLUSIONS
Twelve weeks of 400 microg/day of chromium as a CP supplement did not significantly affect body composition, RMR, plasma glucose, serum insulin, plasma glucagon, serum C-peptide and serum lipid concentrations or iron and zinc indices in moderately obese women placed on an exercise program. The changes in serum total cholesterol levels and TIBC were a result of the exercise program.
Volpe
S L
SL
Department of Nutrition, University of Massachusetts, Amherst 01003, USA. volpe@nutrition.umass.edu
Huang
H W
HW
Larpadisorn
K
K
Lesser
I I
II
D000328:Adult; D001481:Basal Metabolism; D001786:Blood Glucose / Q000032:analysis; D001798:Blood Proteins / Q000378:metabolism; D001823:Body Composition; D002096:C-Peptide / Q000097:blood; D002784:Cholesterol / Q000097:blood; D002857:Chromium / Q000008:administration & dosage* / Q000097:blood / Q000652:urine; D004032:Diet; D019587:Dietary Supplements; D004311:Double-Blind Method; D015444:Exercise; D005215:Fasting; D005260:Female; D005934:Glucagon / Q000097:blood; D006801:Humans; D007328:Insulin / Q000097:blood; D007501:Iron / Q000097:blood / Q000652:urine; D008055:Lipids / Q000097:blood; D008875:Middle Aged; D009765:Obesity / Q000628:therapy*; D010349:Patient Compliance; D010919:Placebos; D015032:Zinc / Q000097:blood
D001786:Blood Glucose; D001798:Blood Proteins; D002096:C-Peptide; D007328:Insulin; D008055:Lipids; D010919:Placebos; D002857:Chromium; D005934:Glucagon; D002784:Cholesterol; D007501:Iron; D015032:Zinc